New oral antithrombotics: a need for laboratory monitoring. Against

被引：55

作者：

Bounameaux, H. ^{[1
]}

Reber, G. ^{[1
]}

机构：

[1] Univ Hosp Geneva & Fac Med, Dept Internal Med, Div Angiol & Hemostasis, Geneva, Switzerland

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2010年 / 8卷 / 04期

关键词：

PARTIAL THROMBOPLASTIN TIME; WEIGHT HEPARIN-THERAPY; FACTOR-XA INHIBITOR; VENOUS THROMBOEMBOLISM; TOTAL HIP; DABIGATRAN; ANTICOAGULANTS; RIVAROXABAN; REPLACEMENT; BAY-59-7939;

D O I：

10.1111/j.1538-7836.2010.03759.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

See also Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. This issue, pp 621-6.

引用

页码：627 / 630

页数：4

共 20 条

[1]

ALHENCGELAS M, 1994, THROMB HAEMOSTASIS, V71, P698

[2]

[Anonymous], J THROMB HAEMOST S2

[3] Pharmacology and management of the vitamin K antagonists [J].

Ansell, Jack ;

Hirsh, Jack ;

Hylek, Elaine ;

Jacobson, Alan ;

Crowther, Mark ;

Palareti, Gualtiero .

CHEST, 2008, 133 (06) :160S-198S

[4] PROSPECTIVE STUDY OF VALUE OF MONITORING HEPARIN TREATMENT WITH ACTIVATED PARTIAL THROMBOPLASTIN TIME [J].

BASU, D ;

CADE, J ;

GALLUS, A ;

HIRSH, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (07) :324-+

[5] Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No [J].

Bounameaux, H ;

De Moerloose, P .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (04) :551-554

[6] Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[7] Monitoring unfractionated heparin with the aPTT: Time for a fresh look [J].

Eikelboom, John W. ;

Hirsh, Jack .

THROMBOSIS AND HAEMOSTASIS, 2006, 96 (05) :547-552

[8] Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement [J].

Eriksson, B. I. ;

Kakkar, A. K. ;

Turpie, A. G. G. ;

Gent, M. ;

Bandel, T. -J. ;

Homering, M. ;

Misselwitz, F. ;

Lassen, M. R. .

JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 2009, 91B (05) :636-644

[9] A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement [J].

Eriksson, Bengt I. ;

Borris, Lars C. ;

Dahl, Ola E. ;

Haas, Sylvia ;

Huisman, Menno V. ;

Kakkar, Ajay K. ;

Muehlhofer, Eva ;

Dierig, Christoph ;

Misselwitz, Frank ;

Kalebo, Peter .

CIRCULATION, 2006, 114 (22) :2374-2381

[10]

GAWOSKI JM, 1987, ARCH PATHOL LAB MED, V111, P785

← 1 2 →